StemCells, Inc. announced that it has transplanted purified human neural stem cells (HuCNS-SC®) into the first five of eight patients in the final cohort of its 16-patient Phase I/II trial for dry AMD.
The trial is currently enrolling patients at five centers at:
Retina Foundation of the Southwest, Dallas, TX
(214) 363-3911
Byers Eye Institute at Stanford, Stanford Hospital and Clinics, Palo Alto, CA
(650) 498-4486
New York Eye and Ear Infirmary, New York, NY
(212) 979-4251
Retina Foundation of the Southwest, Dallas, Texas
(214) 363-3911
Retina Research Institute of Texas, Abilene, TX
(325) 690-4414
The company is expecting to release the first interim results from this study in June, followed by initiation of a controlled Phase II proof-of-concept study later this year.
More information from StemCells, Inc.
Information about the trials.
